Last updated on March 2017

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine


Brief description of study

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Detailed Study Description

The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine

Clinical Study Identifier: TX148086

Find a site near you

Start Over

Cedar Crosse Research Center

800 S Wells, Suite M15 Chicago, IL USA
  Connect »